Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
RCTs are the most reliable way to determine whether a treatment actually works
2018 Oct;43(5):723-725
Retatrutide has passed the early stages and is now in the final stretch
CrossRef Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16) Bum Jun Kim, Hee-Jung Jee, Sun Young Rha, Hye Sook Han, Min-Hee Ryu, Se Hoon Park, Jong Gwang Kim, Woo Kyun Bae, Keun-Wook Lee, Do-Youn Oh, Ji-Hye Byun, Dong Sook Kim, Young Ju Suh, Hyonggin An, Dae Young Zang Gastric Cancer.2022
US$ 29.93
US$ 22.64
US$ 28.93
